Regeneron Pharmaceuticals (REGN) Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q2 2026.

• In Q2 2026, Operating Expenses rose 15.45% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $11.7 billion (up 12.71% YoY), while the FY2025 annual figure was $10.8 billion, up 5.42% from the prior year.
• Operating Expenses for Q2 2026 stood at $3.0 billion, up from $3.0 billion in the prior quarter.
• The five-year high for Operating Expenses was $3.0 billion in Q4 2025, with the low at $1.7 billion in Q1 2022.
• The 5-year median for Operating Expenses is $2.4 billion (2023), against an average of $2.4 billion.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses retreated 2.46% in 2022, then jumped 31.49% in 2023.
• Regeneron Pharmaceuticals' Operating Expenses stood at $2.3 billion in 2022, then gained by 8.55% to $2.5 billion in 2023, then gained by 13.72% to $2.8 billion in 2024, then advanced by 7.34% to $3.0 billion in 2025, then slipped by 0.24% to $3.0 billion in 2026.
• Business Quant data shows REGN's Operating Expenses at $3.0 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.0 billion in Q4 2025.